Literature DB >> 30974124

Subcellular compartmentalization of NAD+ and its role in cancer: A sereNADe of metabolic melodies.

Yi Zhu1, Jiaqi Liu2, Joun Park3, Priyamvada Rai4, Rong G Zhai5.   

Abstract

Nicotinamide adenine dinucleotide (NAD+) is an essential biomolecule involved in many critical processes. Its role as both a driver of energy production and a signaling molecule underscores its importance in health and disease. NAD+ signaling impacts multiple processes that are dysregulated in cancer, including DNA repair, cell proliferation, differentiation, redox regulation, and oxidative stress. Distribution of NAD+ is highly compartmentalized, with each subcellular NAD+ pool differentially regulated and preferentially involved in distinct NAD+-dependent signaling or metabolic events. Emerging evidence suggests that targeting NAD+ metabolism is likely to repress many specific mechanisms underlying tumor development and progression, including proliferation, survival, metabolic adaptations, invasive capabilities, heterotypic interactions with the tumor microenvironment, and stress response including notably DNA maintenance and repair. Here we provide a comprehensive overview of how compartmentalized NAD+ metabolism in mitochondria, nucleus, cytosol, and extracellular space impacts cancer formation and progression, along with a discussion of the therapeutic potential of NAD+-targeting drugs in cancer.
Copyright © 2019. Published by Elsevier Inc.

Entities:  

Keywords:  CD38; NAD(+); NAMPT; NMNAT; PARP; SIRT

Mesh:

Substances:

Year:  2019        PMID: 30974124      PMCID: PMC7010080          DOI: 10.1016/j.pharmthera.2019.04.002

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  266 in total

1.  CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism.

Authors:  Juliana Camacho-Pereira; Mariana G Tarragó; Claudia C S Chini; Veronica Nin; Carlos Escande; Gina M Warner; Amrutesh S Puranik; Renee A Schoon; Joel M Reid; Antonio Galina; Eduardo N Chini
Journal:  Cell Metab       Date:  2016-06-14       Impact factor: 27.287

2.  Overexpression of Sirt6 is a novel biomarker of malignant human colon carcinoma.

Authors:  Chang-Hui Geng; Chun-Ling Zhang; Jing-Yan Zhang; Ping Gao; Miao He; Yan-Lin Li
Journal:  J Cell Biochem       Date:  2018-01-19       Impact factor: 4.429

Review 3.  Regulation and Function of Extracellular Nicotinamide Phosphoribosyltransferase/Visfatin.

Authors:  Federico Carbone; Luca Liberale; Aldo Bonaventura; Alessandra Vecchiè; Matteo Casula; Michele Cea; Fiammetta Monacelli; Irene Caffa; Santina Bruzzone; Fabrizio Montecucco; Alessio Nencioni
Journal:  Compr Physiol       Date:  2017-03-16       Impact factor: 9.090

4.  CD38 enhances the proliferation and inhibits the apoptosis of cervical cancer cells by affecting the mitochondria functions.

Authors:  Shan Liao; Songshu Xiao; Hongxiang Chen; Manying Zhang; Zhifang Chen; Yuehua Long; Lu Gao; Guangchao Zhu; Junyu He; Shuping Peng; Wei Xiong; Zhaoyang Zeng; Zheng Li; Ming Zhou; Xiaoling Li; Jian Ma; Minghua Wu; Juanjuan Xiang; Guiyuan Li; Yanhong Zhou
Journal:  Mol Carcinog       Date:  2017-06-30       Impact factor: 4.784

5.  Lysine glutarylation is a protein posttranslational modification regulated by SIRT5.

Authors:  Minjia Tan; Chao Peng; Kristin A Anderson; Peter Chhoy; Zhongyu Xie; Lunzhi Dai; Jeongsoon Park; Yue Chen; He Huang; Yi Zhang; Jennifer Ro; Gregory R Wagner; Michelle F Green; Andreas S Madsen; Jessica Schmiesing; Brett S Peterson; Guofeng Xu; Olga R Ilkayeva; Michael J Muehlbauer; Thomas Braulke; Chris Mühlhausen; Donald S Backos; Christian A Olsen; Peter J McGuire; Scott D Pletcher; David B Lombard; Matthew D Hirschey; Yingming Zhao
Journal:  Cell Metab       Date:  2014-04-01       Impact factor: 27.287

6.  THE METABOLISM OF TUMORS IN THE BODY.

Authors:  O Warburg; F Wind; E Negelein
Journal:  J Gen Physiol       Date:  1927-03-07       Impact factor: 4.086

Review 7.  NAD Metabolism in Cancer Therapeutics.

Authors:  Keisuke Yaku; Keisuke Okabe; Keisuke Hikosaka; Takashi Nakagawa
Journal:  Front Oncol       Date:  2018-12-12       Impact factor: 6.244

8.  The membrane of peroxisomes in Saccharomyces cerevisiae is impermeable to NAD(H) and acetyl-CoA under in vivo conditions.

Authors:  C W van Roermund; Y Elgersma; N Singh; R J Wanders; H F Tabak
Journal:  EMBO J       Date:  1995-07-17       Impact factor: 11.598

Review 9.  PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancers.

Authors:  Mekonnen Sisay; Dumessa Edessa
Journal:  Gynecol Oncol Res Pract       Date:  2017-11-29

10.  The β-NAD+ salvage pathway and PKC-mediated signaling influence localized PARP-1 activity and CTCF Poly(ADP)ribosylation.

Authors:  David J P Henderson; Jj L Miranda; Beverly M Emerson
Journal:  Oncotarget       Date:  2017-08-03
View more
  22 in total

Review 1.  Decoding the rosetta stone of mitonuclear communication.

Authors:  Justin English; Jyung Mean Son; Maria Dafne Cardamone; Changhan Lee; Valentina Perissi
Journal:  Pharmacol Res       Date:  2020-08-23       Impact factor: 7.658

2.  Intracellular Nampt impairs esophageal squamous cell carcinoma neo-adjuvant chemotherapy response independent of eNampt.

Authors:  Jiahuang Liu; Xiangming Che; Jiangtao You; Guangjian Zhang; Rui Zhao; Junke Fu; Haijun Li
Journal:  Am J Transl Res       Date:  2021-03-15       Impact factor: 4.060

3.  NMNAT promotes glioma growth through regulating post-translational modifications of P53 to inhibit apoptosis.

Authors:  Jiaqi Liu; Xianzun Tao; Yi Zhu; Chong Li; Kai Ruan; Zoraida Diaz-Perez; Priyamvada Rai; Hongbo Wang; R Grace Zhai
Journal:  Elife       Date:  2021-12-17       Impact factor: 8.140

4.  Lipid metabolism-related lncRNA SLC25A21-AS1 promotes the progression of oesophageal squamous cell carcinoma by regulating the NPM1/c-Myc axis and SLC25A21 expression.

Authors:  Yu Liu; Chunxiang Li; Lingling Fang; Liyu Wang; Hengchang Liu; He Tian; Yujia Zheng; Tao Fan; Jie He
Journal:  Clin Transl Med       Date:  2022-06

Review 5.  NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential.

Authors:  Na Xie; Lu Zhang; Wei Gao; Canhua Huang; Peter Ernst Huber; Xiaobo Zhou; Changlong Li; Guobo Shen; Bingwen Zou
Journal:  Signal Transduct Target Ther       Date:  2020-10-07

6.  Quantitative analysis of the human ovarian carcinoma mitochondrial phosphoproteome.

Authors:  Na Li; Shehua Qian; Biao Li; Xianquan Zhan
Journal:  Aging (Albany NY)       Date:  2019-08-22       Impact factor: 5.682

Review 7.  Regulation of Glucose Metabolism by NAD+ and ADP-Ribosylation.

Authors:  Ann-Katrin Hopp; Patrick Grüter; Michael O Hottiger
Journal:  Cells       Date:  2019-08-13       Impact factor: 6.600

8.  Nicotinamide riboside relieves paclitaxel-induced peripheral neuropathy and enhances suppression of tumor growth in tumor-bearing rats.

Authors:  Marta V Hamity; Stephanie R White; Christopher Blum; Katherine N Gibson-Corley; Donna L Hammond
Journal:  Pain       Date:  2020-10       Impact factor: 7.926

Review 9.  Two genomes, one cell: Mitochondrial-nuclear coordination via epigenetic pathways.

Authors:  Meike Wiese; Andrew J Bannister
Journal:  Mol Metab       Date:  2020-02-15       Impact factor: 7.422

Review 10.  NAD- and NADPH-Contributing Enzymes as Therapeutic Targets in Cancer: An Overview.

Authors:  Alvinsyah Adhityo Pramono; Gulam M Rather; Herry Herman; Keri Lestari; Joseph R Bertino
Journal:  Biomolecules       Date:  2020-02-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.